Xap Therapeutics

Xap Therapeutics is an early-stage biotech leveraging genome editing and synthetic biology to engineer a proprietary cell-based delivery platform. The company's core technology involves converting a natural 'first-responder' cell into a modular chassis that can be armed with diverse payloads like cytokines and antibodies, activating only upon target recognition. Based in Cambridge, UK, and founded in 2021, Xap is in a pre-clinical, platform-building phase, targeting significant unmet needs in oncology and autoimmune disorders with a potentially versatile therapeutic approach.

A programmable, cell-based delivery platform created by genome editing and synthetic biology. It engineers a natural 'first-responder' cell into a modular chassis that can be armed with diverse payloads (cytokines, antibodies, nucleic acids) and is designed to activate and release its cargo only upon recognition of specific disease targets.

Xap operates in the competitive field of targeted drug delivery, competing against other cell-based therapies (e.g., CAR-T, engineered macrophages), lipid nanoparticles, antibody-drug conjugates (ADCs), and other targeted modalities. Its differentiation hinges on the unique choice of cell chassis and its proprietary target-activated switching mechanism.